Sheller Can't Show Injury In Risperdal Fight, FDA Says
The U.S. Food and Drug Administration on Tuesday renewed its opposition to claims by Sheller PC that firm had standing to bring a citizen complaint aimed at forcing a Johnson &...To view the full article, register now.
Already a subscriber? Click here to view full article